Metaplanet
3350
Cover
5253
The Why How Do
3823
4
Mitsubishi Heavy Industries
7011
5
Mitsubishi UFJ Financial Group
8306
JP Stock MarketDetailed Quotes
219A Heartseed
- 2104
- 00.00%
20min DelayMarket to Open Apr 16 15:30 JST
47.04BMarket Cap-42.57P/E (Static)
0High0Low0Volume0Open2104Pre Close0.00Turnover388052wk High0.00%Turnover Ratio22.36MShares90152wk Low-49.43EPS TTM15.54BFloat Cap3880Historical HighLossP/E (Static)7.39MShs Float901Historical Low-49.43EPS LYR0.00%Amplitude--Dividend TTM7.10P/B100Lot Size--Div YieldTTM
Heartseed News
Heartseed: Financial Results for the Three Months Ended January 31, 2025 (Under Japan GAAP)(Non-consolidated)
Heartseed: Notice Regarding the Launch of the Analyst Report Issued by Shared Research Inc.
Heartseed: Notice regarding the start of publication of analyst reports by Shared Research Co., Ltd.
Heartseed: Notice Regarding the Completion of the enrollment in Phase 1/2 Clinical Trial (LAPiS Study)
Heartseed: Notice of completion of HS-001 LAPIS test administration
Heartseed: Matters relating to business plans and growth potential
Heartseed: Articles of Incorporation 2025/01/24
Heartseed: Notice regarding changes in the fiscal period (the last day of the fiscal year) and partial changes to the Articles of Incorporation
Heartseed: [Delayed]Financial Results for the Fiscal Year Ended October 31, 2024 (Under Japan GAAP)(Non-consolidated)
Heartseed: Notice Regarding the LAPiS Study Progress
Heartseed: Notice regarding the progress of the HS-001 LAPIS test
Heartseed: Notice Regarding the Revisions of Full-Year Financial Results Forecast for the Fiscal Year Ending October 31, 2024
Heartseed: Notice of completion of safety evaluation committee review on administration of HS-001 LAPIS test high dose group first case
Heartseed: [Delayed] Financial Results for the Nine Months Ended July 31, 2024 (Under Japan GAAP)(Non-consolidated)
Heartseed: Independent Company Executives Declaration
Heartseed: Articles of Incorporation 2024/04/17
Heartseed: Heartseed announced a positive recommendation from the safety monitoring committee regarding dose escalation in Phase 1/2 clinical trials administered with HS-001.
Heartseed: In the HS-001 LAPiS trial, the Safety Evaluation Committee recommended the start of administration in the high-dose group.
Heartseed: Matters related to business plans and growth potential.
Heartseed: Announcements of individual stocks regarding our financial information etc. due to our listing on the Tokyo Stock Exchange Growth Market.